Aclaris Therapeutics, Inc.
NASDAQ:ACRS · NASDAQ Global Select
+$0.03 today
Vol 4.32M · Avg 1.40M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Stock Ticker Earnings Waterfall
NASDAQ:ACRS · Revenue to Net Income
Key Ratios
Analysis
$8.4M of revenue converted into -$69.7M of net income for the selected period. Gross margin is 80.5% and net margin is -958.3%, showing how much revenue survives after costs and taxes. EPS is $-0.56, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $7.8M -58.2% | $18.7M -40.1% | $31.2M +5.0% | $29.8M +340.1% | $6.8M | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $2.1M -25.1% | $2.8M -84.6% | $18.1M +51.2% | $12.0M +153.8% | $4.7M | $725.6M | $804.0M | $882.4M |
| Gross Profit | $5.7M -64.0% | $15.9M +21.0% | $13.2M -26.0% | $17.8M +768.8% | $2.0M | $8.9B | $7.6B | $6.2B |
| Gross Margin | 73.3% -11.8pp | 85.1% +42.9pp | 42.1% -17.7pp | 59.8% +29.5pp | 30.3% | 9.8% | 28.9% | 38.3% |
| Research & Development | $52.6M +56.7% | $33.6M -65.9% | $98.4M +26.4% | $77.8M +77.6% | $43.8M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $22.0M -1.0% | $22.2M -28.6% | $31.1M +23.7% | $25.1M +6.4% | $23.6M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $82.1M -48.0% | $157.9M +42.8% | $110.5M +2.7% | $107.6M +17.3% | $91.8M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $454.0K -43.7% | $807.0K -6.5% | $863.0K +8.3% | $797.0K -13.7% | $923.0K | $374.2M | $1.2B | $631.8M |
| EBITDA | -$64.5M -24.7% | -$51.7M +55.2% | -$115.5M -36.9% | -$84.4M -30.9% | -$64.5M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | -823.8% -547.5pp | -276.3% +93.2pp | -369.5% -85.9pp | -283.5% +669.9pp | -953.4% | 5.6% | 46.3% | 42.0% |
| Operating Income | -$76.4M +46.2% | -$141.9M -45.8% | -$97.4M -8.4% | -$89.9M -0.1% | -$89.7M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | -975.9% -217.7pp | -758.2% -446.6pp | -311.6% -9.5pp | -302.0% +1025.1pp | -1327.1% | 16.6% | 24.1% | 22.0% |
| Interest Income | $7.6M -4.0% | $8.0M | $0 | $0 | $0 | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $0 | $0 | $0 | $0 | $0 | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | $11.5M +16.1% | $9.9M +16.0% | $8.5M +188.8% | $2.9M +358.0% | -$1.1M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | -$64.9M +50.8% | -$132.1M -48.6% | -$88.8M -2.2% | -$86.9M +4.4% | -$90.9M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | -829.6% -124.1pp | -705.5% -421.2pp | -284.3% +7.8pp | -292.1% +1051.8pp | -1344.0% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $0 | $0 +100.0% | -$367.0K | $0 | $0 | $1.3B | -$1.6B | $745.2M |
| Net Income | -$64.9M +50.8% | -$132.1M -49.3% | -$88.5M -1.8% | -$86.9M +4.4% | -$90.9M | $4.9B | $4.8B | $4.7B |
| Net Margin | -829.6% -124.1pp | -705.5% -422.3pp | -283.1% +9.0pp | -292.1% +1051.8pp | -1344.0% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | -$1 +69.0% | -$2 -34.6% | -$1 +4.5% | -$1 +16.9% | -$2 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | -$1 +69.0% | -$2 -34.6% | -$1 +4.5% | -$1 +16.9% | -$2 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $122.7M +58.7% | $77.3M +10.7% | $69.8M +7.0% | $65.2M +15.0% | $56.7M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $122.7M +58.7% | $77.3M +10.7% | $69.8M +7.0% | $65.2M +15.0% | $56.7M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
BioAge Labs, Inc.
NASDAQ:BIOA
$770.69M
Allogene Therapeutics, Inc.
NASDAQ:ALLO
$484.08M
Cabaletta Bio, Inc.
NASDAQ:CABA
$467.15M
908 Devices Inc.
NASDAQ:MASS
$329.17M
NeoGenomics, Inc.
NASDAQ:NEO
$283.66M
Senseonics Holdings, Inc.
NASDAQ:SENS
$272.50M
Editas Medicine, Inc.
NASDAQ:EDIT
$253.56M
Owens & Minor, Inc.
OMI
$207.07M
Exagen Inc.
NASDAQ:XGN
$105.46M
MDxHealth S.A.
MDXH
$27.94M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does ACRS generate?
Aclaris Therapeutics, Inc. (ACRS) reported $7.83M of revenue in fiscal 2025.
Is ACRS profitable?
Aclaris Therapeutics, Inc. (ACRS) reported -$64,923,000.00 of net income, with a net margin of -829.6%.
Explore More
Continue the stock analysis
Jump to another research area for this company.